• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


All the latest conference updates; those that we are attending and the studies that we are presenting

The Neuroimmunology Drug Development Summit is the industry’s definitive and unrivalled forum focused on pushing the frontiers of targeting neuroinflammation for CNS Indications. Transpharmation is proud to be an Event Partner at this meeting and is joining the 80+ neuroimmunology drug development experts to present a poster on our new neuroinflammation models; Evaluation of Human ex vivo and Rodent in vivo Models of Inflammation for CNS Anti-Inflammatory Drug Development, as well as to learn from those pioneering the field, network and build meaningful future partnerships. To discover more about our Neuroimmunology & Neuroinflammation capabilities, please get in touch with us via https://www.transpharmation.co.uk/contact 

To view the work that we presented click here https://youtu.be/NDnTk6y6h3M


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design